{"id":"W4396827653","doi":"10.1016/s1470-2045(24)00178-5","title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Foundation Medicine; Sanofi Genzyme; Chugai Pharmaceutical; University of Texas MD Anderson Cancer Center; EMD Serono; Silverback Therapeutics; Bavarian Nordic; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Seagen; G1 Therapeutics; Genentech; UroGen Pharma; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Amgen; Bladder Cancer Canada; Sanofi; Exelixis; Regeneron Pharmaceuticals; Boston Scientific Corporation; AstraZeneca; Invitae; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Carcinoma in situ; Cystectomy; Bladder cancer; Cohort; Internal medicine; Oncology; Carcinoma; Cancer; Urology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001770008,0.001871316,0.002593186,0.0003745138,0.0004067254,0.00119355,0.0009078087,0.001567128,0.00538899],"category_scores_gemma":[0.00107533,0.000539868,0.001992169,0.0003727356,0.0009502483,0.001496856,0.0003862633,0.003855975,0.001413126],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009506194,"about_ca_system_score_gemma":0.001117897,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001042432,"about_ca_topic_score_gemma":0.002850983,"domain_scores_codex":[0.9996265,0.0001628323,0.00001462648,0.00007781431,0.00002570393,0.00009240308],"domain_scores_gemma":[0.9995338,0.00009999569,0.00008514533,0.00003388653,0.00002934694,0.0002178633],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9174325,0.01141198,0.001187031,0.001625155,0.002450438,0.0001345882,0.0001529158,0.001346903,0.007930716,0.0003471864,0.004497842,0.05148279],"study_design_scores_gemma":[0.9206576,0.07407381,0.002271026,0.0000546268,0.0005044,0.00008883818,0.00004071926,0.0005246663,0.000437238,0.0002358036,0.001092636,0.00001858647],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828838,0.007113093,0.0008449964,0.001421913,0.0006005425,0.002174159,0.001751009,0.0001925252,0.00301798],"genre_scores_gemma":[0.9801033,0.005083583,0.001716795,0.002230628,0.0003354589,0.002558859,0.002758989,0.00004596512,0.005166419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00538899,"threshold_uncertainty_score":0.0180279,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05105573192091713,"score_gpt":0.3836772905862923,"score_spread":0.3326215586653752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}